肯尼亚淋巴丝虫病消除中三联疗法与双联疗法的比较安全性监测:队列事件监测研究
该研究在肯尼亚基利菲和蒙巴萨县开展社区队列事件监测,比较伊维菌素+乙胺嗪+阿苯达唑(IDA)与乙胺嗪+阿苯达唑(DA)在淋巴丝虫病大规模给药中的不良事件。共20421名居民参与,IDA组不良事件发生率27.3%(95%CI 26.4-28.2)显著高于DA组16.2%(95%CI 15.5-16.9),但严重不良事件罕见,IDA总体安全可耐受。
要点
- IDA组不良事件发生率27.3%显著高于DA组16.2%(p<0.0001)。
- 头晕和嗜睡在IDA组更常见,但多为轻中度且短暂。
- 女性、肥胖、服用≥3片乙胺嗪或伊维菌素及已有临床症状是IDA不良事件预测因素。
核心结论
- IDA联合方案在淋巴丝虫病大规模给药中与DA一样安全且耐受良好,无严重危及生命的不良事件。
- IDA治疗的系统性轻中度不良事件及少量严重病例和短暂不良事件比DA治疗更常见。
研究设计与样本
- 社区为基础的前瞻性观察性队列事件监测研究,共纳入20421名合格居民。
- 基利菲县10010人接受DA,蒙巴萨县10411人接受IDA,均通过大规模给药活动给药。
- 给药后第1、2、7天通过挨家挨户访视主动监测不良事件,并交叉核对以区分既往事件与药物相关不良事件。
主要发现
- IDA组2839人报告5807例不良事件,DA组1621人报告3102例不良事件。
- 发生至少一种不良事件的发生率IDA组为27.3%(95%CI 26.4-28.2),DA组为16.2%(95%CI 15.5-16.9),差异显著(p<0.0001)。
- 头晕(IDA 15.9% vs DA 5.9%)和嗜睡(IDA 10.1% vs DA 2.6%)在IDA组显著更高(p<0.0001)。
- 严重不良事件罕见:IDA组0.05%(95%CI 0.35-0.78),DA组0.03%(95%CI 0.14-0.60)。
- 女性、肥胖、服用三片或以上乙胺嗪或伊维菌素以及存在既往临床症状是IDA治疗后不良事件的显著预测因素。
临床怎么用
- 在淋巴丝虫病大规模给药中可选用IDA方案,但需关注头晕、嗜睡等系统性不良事件。
- 建议将药物警戒整合到大规模给药项目中,以及时发现和管理不良事件。
- 对女性、肥胖、服用多片药物及有既往症状者应加强不良事件监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Dual diethylcarbamazine and albendazole (DA) therapy is the standard mass drug administration (MDA) regimen for lymphatic filariasis in Kenya. Following the recent World Health Organization recommendation, Kenya piloted triple therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) in MDA. OBJECTIVE: We conducted a community-based, observational, cohort event monitoring study to compare the types, frequency, severity, and predictors of adverse events following dual versus triple therapy in 20,421 eligible residents. METHODS: Residents in Kilifi (n = 10,010) and Mombasa counties (n = 10,411) received DA and IDA through MDA campaigns, respectively. Adverse events were actively monitored through house-to-house visits on days 1, 2, and 7 after MDA. Any clinical events reported before and after MDA were cross-checked and verified to differentiate pre-existing events from MDA-associated adverse events. RESULTS: Overall, 5807 and 3102 adverse events were reported by 2839 and 1621 individuals in the IDA and DA groups, respectively. The incidence of experiencing one or more adverse events was significantly higher (p < 0.0001) in the IDA group (27.3%; 95% confidence interval [CI] 26.4-28.2) than in the DA group (16.2%; 95% CI 15.5-16.9). Dizziness (15.9% vs 5.9%) and drowsiness (10.1% vs 2.6%) were the most common adverse events and significantly higher in the IDA group compared with the DA group (p < 0.0001). Most adverse events were mild or moderate with a few severe cases (IDA = 0.05%; 95% CI 0.35-0.78, DA = 0.03%; 95% CI 0.14-0.60). Female sex, obesity, taking three or more diethylcarbamazine or ivermectin tablets, and having pre-existing clinical symptoms were significant predictors of adverse events following IDA treatment. CONCLUSIONS: Ivermectin, diethylcarbamazine, and albendazole as a combination is as safe and well tolerated as DA to use in MDA campaigns with no serious life-threatening adverse events. Systemic mild-to-moderate adverse events with a few severe cases and transient adverse events are more common with IDA treatment than with DA treatment. Hence, integrating pharmacovigilance into a MDA program is recommended for the timely detection and management of adverse events.
引用
- Khaemba C, Barry A, Omondi WP, et al. Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study. Drug Saf. 2023. PMID: 37552438. doi:10.1007/s40264-023-01338-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。